- Entheon (ENBI) has appointed David Erritzoe, Clinical Director of Imperial College’s Center for Psychedelic Research, to its Advisory Board
- Erritzoe has significant experience in psychiatry, neuropsychopharmacology and psychedelic research
- He will provide guidance regarding the company’s psychopharmacological research
- Entheon develops and commercializes safe and effective DMT-based psychedelic therapeutic products
- Entheon (ENBI) closed unchanged trading at $0.32 per share
Entheon (ENBI) has appointed David Erritzoe, Clinical Director of Imperial College’s Center for Psychedelic Research, to its Advisory Board.
Erritzoe has significant experience in psychiatry, neuropsychopharmacology and psychedelic research. He is currently leading a new National Health Service-based research clinic, the CIPPRes Clinic, a collaborative, multidisciplinary research initiative between London’s Imperial College and the St. Charles Hospital.
Erritzoe conducts research using brain imaging techniques, including PET and MRI scans, and has conducted research into the neurobiology of addictions and depression.
He will provide guidance regarding Entheon’s psychopharmacological research.
“We continue to research the links between dopamine neurotransmitters and addictions, including the role that functional imaging studies can play in looking at various substance-use disorders,” said Dr. Erritzoe. “As we continue to advance our knowledge in this area, I look forward to working with Entheon as they work to clinically advance DMT.”
Timothy Ko, Entheon’s CEO, commented,
“Dr. Erritzoe’s extensive hands-on experience in the realm of clinical research and his focus on substance-use disorders is a significant addition for Entheon and its Advisory Board as we work to further develop DMT through regulatory channels.”
Entheon develops and commercializes safe and effective DMT-based psychedelic therapeutic products for treating addiction and substance-use disorders.
Entheon (ENBI) closed unchanged trading at $0.32 per share.
